- Home
- BIVI vs CRIS Comparison
BIVI vs CRIS Comparison
Compare BIVI & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- CRIS
- Stock Information
- Founded
- BIVI 2013
- CRIS 2000
- Country
- BIVI United States
- CRIS United States
- Employees
- BIVI N/A
- CRIS N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIVI Health Care
- CRIS Health Care
- Exchange
- BIVI Nasdaq
- CRIS Nasdaq
- Market Cap
- BIVI 15.1M
- CRIS 13.5M
- IPO Year
- BIVI N/A
- CRIS 2000
- Fundamental
- Price
- BIVI $1.10
- CRIS $2.00
- Analyst Decision
- BIVI Strong Buy
- CRIS Strong Buy
- Analyst Count
- BIVI 1
- CRIS 3
- Target Price
- BIVI $30.00
- CRIS $21.00
- AVG Volume (30 Days)
- BIVI 821.9K
- CRIS 106.4K
- Earning Date
- BIVI 05-12-2025
- CRIS 05-06-2025
- Dividend Yield
- BIVI N/A
- CRIS N/A
- EPS Growth
- BIVI N/A
- CRIS N/A
- EPS
- BIVI N/A
- CRIS N/A
- Revenue
- BIVI N/A
- CRIS $11,202,000.00
- Revenue This Year
- BIVI N/A
- CRIS $2.62
- Revenue Next Year
- BIVI N/A
- CRIS $9.84
- P/E Ratio
- BIVI N/A
- CRIS N/A
- Revenue Growth
- BIVI N/A
- CRIS 14.17
- 52 Week Low
- BIVI $0.62
- CRIS $1.02
- 52 Week High
- BIVI $7.50
- CRIS $16.93
- Technical
- Relative Strength Index (RSI)
- BIVI 54.63
- CRIS 51.33
- Support Level
- BIVI $1.05
- CRIS $1.06
- Resistance Level
- BIVI $1.29
- CRIS $2.45
- Average True Range (ATR)
- BIVI 0.14
- CRIS 0.31
- MACD
- BIVI 0.03
- CRIS 0.03
- Stochastic Oscillator
- BIVI 56.18
- CRIS 37.50
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.